Clinical Trials Logo
  1. Home
  2. Germ Cell Tumors
  3. NCT01743482

Pazopanib in Advanced and Cisplatin-resistant Germ Cell Tumors — Pazotest-01  

Germ Cell Tumors Clinical Trial

Official title:
Phase II Study of Single-agent Pazopanib (Votrient®) for Patients With Relapsed or Refractory Germ-cell Tumors (GCT).

Clinical Trial Summary

This is an open label, single arm, single center, phase 2 study with the use of the antiangiogenic multikinase inhibitor pazopanib in a population of patients with germ cell tumors who are not cured following first or subsequent chemotherapy lines for metastatic disease, followed by eventual surgery.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT01743482
Study type Interventional
Source Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Contact
Status Completed
Phase Phase 2
Start date May 17, 2013
Completion date July 27, 2016
View Details
See also
  Status Clinical Trial Phase
Terminated NCT02536183 - A Phase I Study of Lyso-thermosensitive Liposomal Doxorubicin and MR-HIFU for Pediatric Refractory Solid Tumors Phase 1
Completed NCT01505569 - Auto Transplant for High Risk or Relapsed Solid or CNS Tumors N/A
Withdrawn NCT03726281 - Nivolumab in Platinum Recurrent or Refractory Metastatic Germ Cell Tumors Phase 2
Terminated NCT02689219 - Brentuximab Vedotin in Relapsed/Refractory Germ Cell Tumors Phase 2
Completed NCT00864318 - Dose Intensification Study in Refractory Germ Cell Tumors With Relapse and Bad Prognosis Phase 2
Active, not recruiting NCT01873326 - Paclitaxel, Ifosfamide and Cisplatin (TIP) Versus Bleomycin, Etoposide and Cisplatin (BEP) for Patients With Previously Untreated Intermediate- and Poor-risk Germ Cell Tumors Phase 2
Completed NCT00187109 - Recombinant Human Thrombopoietin in Children Receiving Ifosfamide, Carboplatin, and Etoposide Chemotherapy Phase 1/Phase 2
Completed NCT02162732 - Molecular-Guided Therapy for Childhood Cancer N/A
Completed NCT02390843 - Simvastatin With Topotecan and Cyclophosphamide in Relapsed and/or Refractory Pediatric Solid and CNS Tumors Phase 1
Completed NCT04283773 - Immunohistochemical Evaluation of Protein P16 Expression in Ovarian Germ Cell Tumors.
Completed NCT00572572 - Aprepitant + a 5HT3 + Dexamethasone in Patients With Germ Cell Tumors Phase 3
Completed NCT02161692 - Conventional Dose Versus High Dose Sequential Chemotherapy for Poor Prognosis Germ Cell Tumors Phase 2
Withdrawn NCT04648826 - Aerosolized Azacytidine as Epigenetic Priming for Bintrafusp Alfa-Mediated Immune Checkpoint Blockade in Patients With Unresectable Pulmonary Metastases From Sarcomas, Germ Cell Tumors, or Epithelial Malignancies Phase 1/Phase 2